TNF and myeloid sarcoma: Even exogenous administration of TNFα to TNFα KO mice rescued them from further severe EAE, while clinical trials in MS patients treated with a soluble TNFα receptor (Lenercept) resulted in clinical worsening and had to be discontinued [43, 44].